本帖最后由 maicon08 于 2023-4-28 15:12 编辑
# h7 K2 _; i" I- s0 z# k" e5 p
; V, S! }3 O. o5 w一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。- ]7 p: Q( O0 m1 @. m7 h T c9 v
+ m- c0 W. t& chttps://www.163.com/dy/article/I3BTTPRD053438SI.html1 l2 G8 z& A& g( c3 F5 G
9 p- A$ \3 {7 X- x, \, a: ^& T/ N
# B3 \9 f% I1 v; o5 K1 }在研疗法-免疫治疗
) ?( L8 p1 z4 ^# T- a5 sDevelopmental Therapeutics—Immunotherapy
2 o! T- V3 ^% v
' X) U+ V( ]7 u. H$ U5 x& w" V摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 p. J. }7 {1 ]; S4 `0 x4 U
在研疗法-分子靶向药物和肿瘤生物学
: }5 u) ?, v/ a Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology e# P1 G; h% z, [- U
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 % C, n) {& f/ h4 W
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 9 |& W; Y! P# o1 l
胃肠道肿瘤-结直肠癌和肛门癌
% i7 `$ D/ F, j" B Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
8 K" u: C+ i8 P: K1 T0 W7 U
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ) d( V* b, T# U7 f4 M2 _
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
" W9 F' U; p) b6 ]: i
妇科肿瘤 Gynecologic Cancer - C% X# I* b; l1 z0 i
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
4 D! G8 r# c4 }
头颈肿瘤, G6 X+ _. E/ Y- P
Head and Neck Cancer " F* e* x% N* C
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 ! C5 x: [, w0 C( u2 @
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 ( E5 n) b; n0 l7 i# L8 q
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 " h& D5 l9 G. J- P0 T5 f& S0 i1 |8 c
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia 6 z2 L* K! `# v
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 0 ?0 Q* v3 K, }4 L$ L
血液系统恶性肿瘤-浆细胞疾病
s' W( C* f& W5 [2 @ Hematologic Malignancies—Plasma Cell Dyscrasia * W. m0 ^ R9 J8 b& ]
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 ) f% W: M) f6 d8 {- O
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
1 m7 b( v% n l4 W% {. H Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 9 Z) q: M1 X! a3 H w; [! u* F8 D
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
; J$ ]1 X5 W1 R. [, k* j
肺癌-转移性非小细胞肺癌4 G' B Q/ J5 D3 e2 a/ J: k+ M2 B+ K
Lung Cancer—Non-Small Cell Metastatic + ~% X$ L5 q! L0 Z2 r
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
. L" b$ S, Y* J) C/ `5 _
: m+ A9 t) v5 f$ I
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 4 q J& ]. j! P7 v( F
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
6 J) p3 T8 F0 [
黑色素瘤/皮肤癌
/ }2 t2 l* J) \7 q2 Q3 O Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 $ s8 V" b7 s9 S! B+ a6 b1 K! c$ R
快速摘要报告
6 [& c% k. @- G. ?, Z0 a Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
$ F0 ^) |+ f o
临床科学研讨会7 R* G0 P$ | l& ?
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
' e' B- ^+ z& d% P/ k
. e: A/ ^# |/ T* b5 U: m, a9 h' C( C) V | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
